The abstract is read at the publisher; the summary is JClub's.
Mini-19484, a de novo designed miniprotein binder, binds the leptin receptor (LEPR) CRH2 domain with a 30 nM dissociation constant and a stable helical fold.
- Why it matters: Modulating LEPR signaling is a therapeutic strategy for obesity and related metabolic disorders, but targeting the leptin-binding site with engineered binders remains challenging.
- What they did: The team used de novo computational design with screening, then performed biochemical characterization and structural analysis plus mutagenesis to identify Arg18 as a binding hotspot.
- The result: Mini-19484 shows enhanced resistance to proteolytic degradation and a binding mode distinct from natural leptin, enabling a new scaffold for LEPR CRH2-targeted miniprotein therapeutics.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.